Actinogen Medical Limited
ATGGF · OTC
6/30/2025 | 6/30/2024 | 6/30/2023 | 6/30/2022 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.34 | -0.71 | -0.45 | -0.07 |
| FCF Yield | -8.39% | -34.64% | -23.87% | -15.32% |
| EV / EBITDA | -5.15 | -3.08 | -1.85 | -3.61 |
| Quality | ||||
| ROIC | -69.13% | -36.42% | -78.40% | -41.69% |
| Gross Margin | 100.00% | 100.00% | 91.70% | 88.99% |
| Cash Conversion Ratio | – | 1.30 | 0.81 | 1.00 |
| Growth | ||||
| Revenue 3-Year CAGR | 3.95% | 39.73% | 35.06% | 1.16% |
| Free Cash Flow Growth | 55.22% | -94.15% | 8.25% | -450.26% |
| Safety | ||||
| Net Debt / EBITDA | 0.88 | 0.71 | 0.55 | 1.27 |
| Interest Coverage | 0.00 | -528.53 | -637.36 | -494.22 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 385.41 | 346.41 | -701.18 | -423.45 |